FR054|cas:35954-65-5|西域试剂

FR054,95.0%

产品编号：Bellancom-124909A| CAS NO：35954-65-5| 分子式：C₁₄H₁₉NO₈| 分子量：329.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124909A	￥500.00	杭州北京（现货）
Bellancom-124909A	￥750.00	杭州北京（现货）
Bellancom-124909A	￥1600.00	杭州北京（现货）
Bellancom-124909A	￥2500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FR054

产品介绍

FR054 是 HBO 酶 PGM3 的抑制剂，具有明显的抗乳腺癌活性。

生物活性

FR054 is an inhibitor of the HBP enzyme PGM3, with a remarkable anti-breast cancer effect.

体外研究

FR054 (0.5-1 mM, 24-48 h) induces an early proliferation arrest followed by a marked cell death increase in breast cancer cells and induces apoptosis. The effect of FR054 occurs through PGM3 inhibition instead of other off-target effects.
FR054 (250 μM, 24 h) treatment efficiently affects both N- and O-glycosylation levels in MDA-MB-231 cells.
FR054 induces endoplasmic reticulum (ER) stress and a ROS-dependent apoptotic cell death.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	MDA-MB-231 cells.
Concentration:	0.5-1 mM.
Incubation Time:	48 h.
Result:	Reduced viability and a significant increase of the apoptosis as compared to the control clone.

体内研究
(In Vivo)

FR054 (1000 mg/kg, ip) suppresses cancer growth in MDA-MB-231 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice were subcutaneously injected with MDA-MB-231 cells.
Dosage:	1000 mg/kg.
Administration:	IP, single or fractionated dose (twice a day 500 mg/kg/dose).
Result:	Appears to have an in vivo antitumor efficacy that is higher when administered twice a day compared to single administration.

体内研究

FR054 (1000 mg/kg, ip) suppresses cancer growth in MDA-MB-231 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice were subcutaneously injected with MDA-MB-231 cells.
Dosage:	1000 mg/kg.
Administration:	IP, single or fractionated dose (twice a day 500 mg/kg/dose).
Result:	Appears to have an in vivo antitumor efficacy that is higher when administered twice a day compared to single administration.

体内研究

FR054 (1000 mg/kg, ip) suppresses cancer growth in MDA-MB-231 xenograft mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice were subcutaneously injected with MDA-MB-231 cells.
Dosage:	1000 mg/kg.
Administration:	IP, single or fractionated dose (twice a day 500 mg/kg/dose).
Result:	Appears to have an in vivo antitumor efficacy that is higher when administered twice a day compared to single administration.

性状

Oil

溶解性数据

In Vitro:

DMSO : 100 mg/mL (303.67 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0367 mL	15.1837 mL	30.3674 mL
5 mM	0.6073 mL	3.0367 mL	6.0735 mL
10 mM	0.3037 mL	1.5184 mL	3.0367 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.59 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.59 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。